Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Diagnostic
- Drug Discovery
- Disease
- Therapeutic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 369310
Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof;
Device and method for treating restenosis;
Inhibition of Phosphatidylinositol 3-kinase with wortmannin analogs;
Device and Method for Treating Restenosis; and,
Wortmannin Analogs and Methods of Using Same.
IPSCIO Record ID: 369309
3,4-Dideoxyn Phosphatidylinositol Ether Lipid Analog Inhibitors of Myo-Inositol Cycle;
Deoxy Phosphatidyl Inositol Analogs with Anti tumor Activity;
3-Substituted 3-Deoxy-Phosphatidyl Myo-Inositol Inhibitors of PTEN; and,
Inositol Ether Lipid Analogs and Methods of Using Same.
Licensee is a clinical-stage biopharmaceutical company focused primarily on the development and commercialization of therapeutic products for the treatment of cancer.
IPSCIO Record ID: 6906
assigned to the Arizona Board of Regents and Eli Lilly and Company, now abandoned;
Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof. Abstract – Wortmannin and certain of its analogs are inhibitors of phosphatidylinositol 3-kinase. The compounds are particularly useful for inhibiting phosphatidylinositol 3-kinase in mammals and for treating phosphatidylinositol 3-kinase-dependent conditions, especially neoplasms, in mammals.
U.S. Patent Application No. 10/245,780 filed
9/16/2002, now U.S. Patent No. 6,703,414 issued 3/09/2004 assigned to
Arizona Board of Regents, and The Burnham Institute;
U.S. Patent Application No. 10/245,779 filed
9/16/2002, now U.S. Patent No. 7,081,475 issued 7/25/2006 assigned to Arizona Board of Regents and University of Pittsburgh;
U.S. Patent Application No. 11/279,000 filed
4/07/2006, now U.S. Patent No. 7,335,679 issued 2/26/2008 assigned to Arizona Board of Regents and University of Pittsburgh;
U.S. Patent Application No. 11/178,553 filed
7/11/2005, now U.S. Patent No. 7,446,124 issued 11/04/2008 assigned to Arizona Board of Regents, Prolx Pharmaceuticals, Inc. and University of Pittsburgh;
U.S. Patent Application No. 11/618,036 filed 12/30/2005;
U.S. Patent Application No. 11/858,508
U.S. Patent Application No. 12/235,730 filed 9/23/20008
U.S. Patent Application No. 12/752,935 filed 4/1/2010
